Phagelux (菲吉乐科) is a Chinese agri-biotech company that develops bacteriophage- and lysin-based biological alternatives to antibiotics and chemical pesticides, with product lines spanning crop science, animal health, food safety and feed additives. Founded by American entrepreneur Mark Engel in the early 2010s with incubation from Fosun Pharma, the group is headquartered in Wuxi, Jiangsu, and operates R&D labs and manufacturing in both China and North America, maintaining one of the largest commercial agricultural phage libraries with bio-pesticide registrations in Chinese and overseas markets.
1
Round
1
Industry
4
Tags
Aug 31, 2026
Latest raise
Funding activity · 1 round
Aug 31, 2026
CNY -1
Series B
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
